No evidence to support use of vitamin C supplementation in cancer
the ONA take:
According to a new study published in the journal The Oncologist, researchers have found that there is no high-quality evidence to support the use of ascorbate (vitamin C) supplementation to enhance efficacy or reduce toxicity of chemotherapy in patients with cancer.
For the systematic review, researchers from the Ottawa Hospital Cancer Centre Division of Medical Oncology in Ottawa, Ontario, Canada, sought to investigate whether supplemental ascorbate synergizes the anticancer effects of chemotherapy and reduces its toxicity.
Researchers identified 34 articles to be included in the study from Medline, EMBASE, and the Cochrane central register. Among those, there were five randomized controlled studies, 12 phase 1/2 studies, six observational trials, and 11 case reports.
The studies included a total of over 8,000 patients. Results showed no statistically significant improvements in overall survival or progression-free survival or reduced toxicity with supplemental ascorbate use compared with the control arm.
The authors note that high-quality placebo-controlled studies are needed to assess the effects of ascorbate on chemotherapy efficacy and toxicity in patients with cancer.
No high-quality evidence to support the use of ascorbate (vitamin C) supplementation to enhance cancer treatment.
- Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma
- Fertility Preservation in Male Adolescents and Young Adults With Cancer
- Social, Psychiatric Variables Reduce Cognitive Functioning, QoL in HNC
- Impact of Prostate Cancer Diagnosis, Treatment Choice on Quality of Life
- Duloxetine May Improve AI-Associated Joint Pain in Early Stage Breast Cancer
- HPV and Cancer (Fact Sheet)
- Pain Control More Easily Achieved With Nurse-Led Education in Bone Metastases
- Acupuncture an Effective Alternative Treatment for Cancer-Related Fatigue
- Using Nutrition-Based Strategies to Manage Adverse Effects of Cancer
- Palliative Care Associated With Decreased Costs For Patients With Advanced Cancer
- Exercise May Mitigate Doxorubicin-related Cardiotoxicity
- Reduced Delayed Intensification Impacts Risk of Pediatric ALL Relapse
- Exercise May Mitigate Cardiotoxicity Associated With Doxorubicin Treatment
- Mobile Health Apps Becoming More Popular Among Patients and Clinicians
- Online Learning Modules Improve Exercise Counseling, But Not Participation
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|